title: Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy.
abstract: OBJECTIVE
  To determine the factors that can improve the prediction of biochemical recurrence after radical prostatectomy for the patients with prostate adenocarcinoma.
  
  
  METHODS
  Our study included 182 patients with prostate adenocarcinoma who were biopsied and underwent radical surgical treatment at the Clinic of Urology, Clinical Center of Serbia, Medical Faculty in Belgrade from 1994 to 2004. Patients were prospectively followed-up and monitored for a minimum of 8 years and data were statistically processed by multivariate regression analysis. We arranged the predictors into 3 regressive models. In the first model the predictors were clinical stage of the disease, preoperative Gleason score, F/T PSA ratio and PSA. In the second model these predictors were accompanied with the number of positive biopsies and percent of positive prostate biopsies. In the third model, patient follow-up was added to the predictors. In all 3 models biochemical recurrence was considered as a dependent variable.
  
  
  RESULTS
  On multivariate analysis, patient follow-up (p<0.0001), percent of positive prostate biopsies (p<0.0001), bioptic Gleason score (p<0.0001) and preoperative PSA (p<0.003) were significant independent predictors of biochemical recurrence. The most successful prediction of recurrence that provided accurate prognosis for 80% of the patients was obtained by the third model using the percent of positive prostate biopsies, PSA and patient follow-up.
  
  
  CONCLUSIONS
  As stated in multivariate analysis, the independent predictors according to the significance are the follows: patient follow-up, percent of positive prostate biopsies, bioptic Gleason score and preoperative PSA, whereas preoperative F/T PSA ratio is dependent predictor. The number of positive biopsies and clinical stage of the disease are of no significance.
authors.affiliation: Clinic of Urology, Clinical Center of Serbia, Medical Faculty, Belgrade, Serbia.
authors.forename: M
authors.initials: M
authors.lastname: Acimovic
authors.forename: K
authors.initials: K
authors.lastname: Dabic-Stankovic
authors.forename: T
authors.initials: T
authors.lastname: Pejcic
authors.forename: Z
authors.initials: Z
authors.lastname: Dzamic
authors.forename: D
authors.initials: D
authors.lastname: Rafailovic
authors.forename: J
authors.initials: J
authors.lastname: Hadzi-Djokic
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology / Q000601:surgery*; D001706:Biopsy; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D016014:Linear Models; D008297:Male; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D016017:Odds Ratio; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000601:surgery*; D018570:Risk Assessment; D012307:Risk Factors; D055771:Serbia; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen